The Technical Analyst
Select Language :
Aptorum Group Ltd [APM]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Aptorum Group Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals

Aptorum Group Ltd is listed at the  Exchange

9.08% $9.49

America/New_York / 28 mar 2024 @ 16:00


Aptorum Group Ltd: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 39.59 mill
EPS: -2.41
P/E: -3.94
Earnings Date: Sep 29, 2023
SharesOutstanding: 4.17 mill
Avg Daily Volume: 2.47 mill
RATING 2024-03-28
B-
Sell
RATINGS
Rating CashFlow: Neutral
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Neutral
P/E: Sell
Price To Book: Neutral
QUARTER GROWTHS
2/214/212/224/221/232/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/an/an/an/an/an/a
Ebitn/an/an/an/an/an/a
Asset n/an/an/an/an/a
Debtn/an/an/an/an/a
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -3.94 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.67x
Company: PE -3.94 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 7.80 - 11.19

( +/- 17.86%)
ATR Model: 14 days

Forecast: 16:00 - $9.53

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $9.53
Forecast 2: 16:00 - $9.53
Forecast 3: 16:00 - $9.53
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $9.49 (9.08% )
Volume 0.211 mill
Avg. Vol. 2.47 mill
% of Avg. Vol 8.54 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Aptorum Group Ltd

Last 12 Months

Last 12 months chart data with high, low, open and close for Aptorum Group Ltd

RSI

Intraday RSI14 chart for Aptorum Group Ltd

Last 10 Buy & Sell Signals For APM

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Aptorum Group Ltd

APM

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

Last 10 Buy Signals

Date Signal @
KUBUSDMar 28 - 19:082.69
FISUSDMar 28 - 19:030.952
PROPCUSDMar 28 - 18:585.09
XCADUSDMar 28 - 18:571.490
INDEXUSDMar 28 - 18:565.95
FUMOUSDMar 28 - 18:5410 001
ALPHUSDMar 28 - 18:542.71
HNTUSDMar 28 - 18:47$6.19
WBTUSDMar 28 - 18:438.37
TRXUSDMar 28 - 18:39$0.120

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.